Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

about

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers

P2860

Q47209071-FC4AD936-0946-422F-AAD3-B65FAB753513 Q52562930-3530EAEF-D029-4ACF-B60E-CE640C069FB0 Q58737377-C0F50516-CE26-491E-BC37-EB921110A023

P2860

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

Item

http://www.wikidata.org/entity/Q45072406

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@en

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@nl

type

Item

label

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@en

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@nl

prefLabel

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@en

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@nl

P1476

Phase Ib/II study of gemcitabi ...... tic pancreatic adenocarcinoma.

@en

P2093

Ekkhard Schütz

http://www.w3.org/2001/XMLSchema#string

Glen J Weiss

http://www.w3.org/2001/XMLSchema#string

Howard Urnovitz

http://www.w3.org/2001/XMLSchema#string

Julia Beck

http://www.w3.org/2001/XMLSchema#string

Kirsten Bornemann-Kolatzki

http://www.w3.org/2001/XMLSchema#string

Lisa Blaydorn

http://www.w3.org/2001/XMLSchema#string

Vivek Khemka

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Nivolumab plus ipilimumab in advanced melanoma.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation

Immune checkpoint therapy for pancreatic cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

P2888

s10637-017-0525-1

P31

scholarly article

P356

10.1007/S10637-017-0525-1

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092593872

http://www.w3.org/2001/XMLSchema#string

P698

29119276

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

about

P2860

P2860

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698

P921